Previous Pause Next
Home >> News Center >> Swine Flu >>
Therapy and Treatment
H1N1 Patients With Respiratory Failure That Are Treated With Oxygenating System Have Lower Risk Of Death PDF Print E-mail
Saturday, 08 October 2011 07:11

According to an investigation in JAMA, individuals who developed respiratory failure after being infected with severe 2009 H1N1 influenza, and who received treatment with a system that adds oxygen to their blood, had a lower rate of dying in hospital compared to those who did not receive the treatment.

The investigation is being published early online to accompany its presentation at the European Society of Intensive Care Medicine meeting being held in Berlin.

Powerful X-Rays Enable Development of Successful Treatment for Melanoma and Other Life-Threatening Diseases PDF Print E-mail
Friday, 19 August 2011 23:42
Powerful X-ray technology developed at the U.S. Department of Energy's (DOE's) national laboratories is revealing new insights into diseases ranging from Alzheimer's to the swine flu, and, most recently, enabled the discovery of a groundbreaking new drug treatment for malignant melanoma, the deadliest form of skin cancer. The drug, Zelboraf (vemurafenib), has just received U.S. Food and Drug Administration (FDA) approval. In showing the structures of diseased and disease-causing molecules at their basic level, these extremely bright light sources enable scientists to suggest potential new treatments.
NanoViricides Reports Treatment With Its FluCide Drug Candidate Achieves Dramatic Full Survival In Recent H1N1 Influenza Lethality Study PDF Print E-mail
Wednesday, 23 March 2011 12:37

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reported dramatically improved antiviral efficacy with its optimized FluCide™ drug candidates in its most recent animal study. In the influenza mouse lethal infection model, animals treated with one of the optimized FluCide™ nanoviricide drug candidates survived beyond the stated full duration of study (21 days), and those treated with two additional drug candidates survived almost the full duration of the study. Animals in these three groups survived significantly longer (20.2 to 22.2 days) as compared to the animals treated with Oseltamivir (Tamiflu®; only 8.3 days).

Possible New Treatment for Severe 2009 H1N1 Infection PDF Print E-mail
Saturday, 22 January 2011 05:13
Convalescent plasma therapy -- using plasma from patients who have recovered from an infection to treat those with the same infection -- has been used to treat multiple diseases. However, the efficacy of this treatment in patients with severe 2009 H1N1 influenza is unknown. A study published in the February 15 issue of Clinical Infectious Diseases suggests that convalescent plasma may reduce the death rate in patients severely ill with this type of influenza.
Young Adults Killed During Pandemic Flu By Over-Reactive Immune Systems PDF Print E-mail
Thursday, 09 December 2010 06:03

On November 19, Jason Martin returned to the Medical Intensive Care Unit (MICU) at Vanderbilt University Medical Center for the first time since he nearly died there during last year's H1N1 flu pandemic. The tall and burly Warren County, TN, ambulance worker - a 30-year-old, father of three young children - broke down and hugged some of the nurses he recognized.

"I got sick on September 12 and didn't come out of it for the next 20 days. I am just so grateful I came through," Martin said, wiping his eyes.

Over-Reactive Immune System Kills Young Adults During Pandemic Flu PDF Print E-mail
Tuesday, 07 December 2010 04:07
A hallmark of pandemic flu throughout history, including the 2009 H1N1 pandemic, has been its ability to make healthy young and middle-aged adults seriously ill and even kill this population in disproportionate numbers. In a paper published Dec. 5 in Nature Medicine, Vanderbilt University Medical Center researchers provide a possible explanation for this alarming phenomenon of pandemic flu. The study's findings suggest people are made critically ill, or even killed, by their own immune response.
Cegedim Strategic Data's Real World Evidence Helping Epidemic Surveillance PDF Print E-mail
Saturday, 30 October 2010 01:29

During the Flu epidemic A/H1N1 in 2009, the trends published by Cegedim Strategic Data (CSD) through the use of their Longitudinal Patient Database (LPD) concerning seasonal influenza, Flu A/H1N1, and flu-like syndrome aligned closely with those published by governmental institutions (Sentinelles Network). The LPD peak trends of flu-related diagnoses were slightly in advance compared to those of the Sentinelles Network.

59% Of Americans Thought To Be Immune To H1N1 (Swine Flu) PDF Print E-mail
Thursday, 30 September 2010 04:04

Approximately 183 million Americans, or 59% of the country's population are thought to be immune to the H1N1 virus that caused a pandemic in 2009, according to estimates by scientists at the National Institute of Allergy and Infectious Diseases, part of the NIH (National Institutes of Health). They are also attempting to speculate where *pH1N1 will go from here by reviewing the fate of some that took place in history.

Children With H1N1 Flu More Susceptible To Seizures Than With Seasonal Flu PDF Print E-mail
Thursday, 23 September 2010 07:21

The 2009 A(H1N1) swine flu pandemic caused a higher incidence of neurological complications - especially seizures and encephalopathy (brain malfunction or damage) - in children than normal seasonal flu, scientists from the University of Utah, Clinical Neurosciences Center revealed in an article published in Annals of Neurology.

Aganocide Compounds Prove Effective Against H1N1 Influenza Virus PDF Print E-mail
Saturday, 18 September 2010 00:56

Fears over the influenza A virus (H1N1; sometimes referred to as swine flu) have motivated researchers to investigate the antimicrobial activity of the Aganocide® compounds against viruses. In a study presented at this year's Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), a team led by Professor Markus Nagl, MD of Medical University of Innsbruck and including D. Debabov, PhD and K. Hybiske, PhD of NovaBay Pharmaceuticals evaluated the in vitro virucidal activity of three compounds: N-chlorotaurine (NCT), a compound produced by human phagocytes; and two NCT analogs, NVC-612 and NVC-422.

Treatment With Oxygenating System Associated With Lower Risk of Death for H1N1 Patients With Respiratory Failure PDF Print E-mail
Thursday, 06 October 2011 00:57
Patients with severe 2009 H1N1 influenza who developed respiratory failure and were treated with a system that adds oxygen to the patient's blood had a lower rate of in-hospital death than similar patients who did not receive this treatment, according to a study appearing in JAMA. The study is being published early online to coincide with its presentation at the European Society of Intensive Care Medicine meeting in Berlin.
New Approach to Defeating Flu Shows Promise PDF Print E-mail
Saturday, 23 April 2011 07:45
New research on mice has shown that pulmonary administration of granulocyte macrophage-colony stimulating factor (GM-CSF) significantly reduces flu symptoms and prevents death after a lethal dose influenza virus. While GM-SCF therapy for humans as a flu prophylaxis or treatment may be years away, the study results were striking: All of the mice treated with GM-SCF survived after being infected with the influenza virus, whereas untreated mice all died from the same infection.
Size of Airborne Flu Virus Impacts Risk, Researchers Say PDF Print E-mail
Wednesday, 02 February 2011 18:15
A parent's wise advice to never go to a hospital unless you want to get sick may be gaining support from scientific studies on a specific airborne virus.

The results of a Virginia Tech study by environmental engineers and a virologist on the risk of airborne infection in public places from concentrations of influenza A viruses is appearing in the online, Feb. 2 issue of the United Kingdom's Journal of the Royal Society Interface.

Doctors Encourage Patients To Get Their Flu Vaccination To Reduce Risk Of Serious Illness, Scotland PDF Print E-mail
Saturday, 18 December 2010 00:09

With reports of an increase in H1N1 cases emerging in Scotland, doctors urged patients who are eligible for the winter flu vaccination to contact their GP practice.

The vaccine programme continues throughout the winter months for those people most at risk from the flu bug.

By having the vaccination, patients aged over 65 and those under 65 'at risk' can protect themselves from the effects of flu, and in doing so, reduce winter pressure on Scotland's busy hospitals.

Increasing Drug Resistance And Ability To Spread In Influenza Virus Strains PDF Print E-mail
Thursday, 09 December 2010 05:37

Two new studies raise public health concerns about increasing antiviral resistance among certain influenza viruses, their ability to spread, and a lack of alternative antiviral treatment options. The findings are published in the January 1 issue of The Journal of Infectious Diseases.

Influenza viruses are treated with two classes of drugs: M2 blockers (adamantanes) and neuraminidase inhibitors (NAIs), including oseltamivir and zanamivir.

Severe Form Of Influenza Can Be Treated More Effectively PDF Print E-mail
Saturday, 04 December 2010 04:42

Flu season is upon us and while getting the nasty bug is bad news, the good news is it's now possible to treat the severe form of the virus more effectively, according to a Ryerson University researcher. Though Canada is not expecting a pandemic flu season this winter Health Canada reports that about 4,000 to 8,000 Canadians die each year from flu-related pneumonia.

H1N1 Flu Linked To Serious Bacterial Infections In Children PDF Print E-mail
Wednesday, 27 October 2010 19:15

The H1N1 influenza pandemic has led to a sharp increase in the number of children with a serious "secondary" bacterial infection called empyema in children, suggests a study in the October issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

Higher Incidence of Seizures Seen in Children With H1N1 Virus Compared to Seasonal Flu PDF Print E-mail
Friday, 24 September 2010 19:02
A recent study by researchers at the University of Utah determined that the 2009 pandemic influenza A (H1N1) caused a higher rate of neurological complications in children than the seasonal flu. The most common complications observed were seizures and encephalopathy.
'Friendship Paradox' May Help Predict Spread of Infectious Disease PDF Print E-mail
Tuesday, 21 September 2010 05:43
Your friends are probably more popular than you are. And this "friendship paradox" may help predict the spread of infectious disease.

Nicholas Christakis, professor of medicine, medical sociology and sociology at Harvard University, and James Fowler, professor of medical genetics and political science at the University of California, San Diego, used the paradox to study the 2009 flu epidemic among 744 students.

Compared To Recent Flu Strains, Individuals With 2009 H1N1 Infections Had Lower Risk Of Most Serious Complications, Were Younger PDF Print E-mail
Wednesday, 08 September 2010 17:40

An analysis of data from influenza cases in Wisconsin indicates individuals with 2009 H1N1 infections were younger than those with H3N2 (2007-2008), and that the risk of most serious complications was not higher in adults or children with 2009 H1N1 compared with recent seasonal strains, according to a study in the September 8 issue of JAMA.

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 11